Immune checkpoint inhibitors and other immune therapies in breast cancer: A new paradigm for prolonged adjuvant immunotherapy

A Nicolini, P Ferrari, A Carpi - Biomedicines, 2022 - mdpi.com
Background: Breast cancer is the most common form of cancer in women worldwide.
Advances in the early diagnosis and treatment of cancer in the last decade have …

Evolving management of HER2+ breast cancer brain metastases and leptomeningeal disease

MN Mills, W King, A Soyano, Y Pina… - Journal of Neuro …, 2022 - Springer
Patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer are at
a particularly high risk of breast cancer brain metastasis (BCBM) and leptomeningeal …

Evolutionary trend analysis of research on immunotherapy for brain metastasis based on machine-learning scientometrics

X Hu, X Deng, J **e, H Zhang, H Zhang, B Feng, Y Zou… - Pharmaceuticals, 2024 - mdpi.com
Brain metastases challenge cancer treatments with poor prognoses, despite ongoing
advancements. Immunotherapy effectively alleviates advanced cancer, exhibiting immense …

Immunotherapy and radiation therapy sequencing in breast cancer: a systematic review

S Verma, S Young, G Boldt, P Blanchette… - International Journal of …, 2024 - Elsevier
Purpose In the past decade, immune checkpoint inhibitors (ICIs) have emerged as a
treatment option for metastatic breast cancer (BC). More recently, ICIs have been approved …

Radiotherapeutic strategies to overcome resistance of breast cancer brain metastases by considering immunogenic aspects of cancer stem cells

K Hintelmann, C Petersen, K Borgmann - Cancers, 2022 - mdpi.com
Simple Summary Modern radiotherapy offers several options for the treatment of brain
metastases from breast cancer. The radioresistant subpopulation of cancer stem cells …

Long-term survival from breast cancer brain metastases in the era of modern systemic therapies

E Mashiach, JD Alzate, FDN Vasconcellos… - …, 2022 - journals.lww.com
METHODS: We reviewed 190 patients with breast cancer with 931 brain tumors receiving
SRS who were followed at our institution with prospective data collection between 2012 and …

[HTML][HTML] Stereotactic radiosurgery and anti-PD-1+ CTLA-4 therapy, anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitors, or conventional …

AE Dohm, JY Nakashima, H Kalagotla, SX Jiang… - European Journal of …, 2023 - Elsevier
Background Immunotherapy and targeted BRAF/MEK inhibitors (i) have revolutionised the
systemic management of advanced melanoma. Given the role of stereotactic radiosurgery …

Triple Negative Breast Cancer and Brain Metastases

R Bansal, AED Van Swearingen… - Clinical Breast …, 2023 - clinical-breast-cancer.com
The treatment of metastatic breast cancer (MBC) has improved over the past decade,
however prognosis continues to be mitigated by the fact that about 1 in 5 patients with MBC …

Intracranial response rate in patients with breast cancer brain metastases after systemic therapy

A Niwinska, K Pogoda, A Jagiello-Gruszfeld… - Cancers, 2022 - mdpi.com
Simple Summary For many years, patients with breast cancer and brain metastases were
excluded from participation in clinical trials. It was believed that anticancer drugs could not …

Phase II Trial of Brain MRI Surveillance in Stage IV Breast Cancer

KA Ahmed, Y Kim, AJ Armaghani, JA Arrington… - Neuro …, 2025 - academic.oup.com
Background Screening of asymptomatic stage IV breast cancer with brain MRIs is currently
not recommended by National Comprehensive Cancer Network (NCCN) Guidelines. The …